Edgewise Therapeutics (EWTX) Income from Continuing Operations (2020 - 2026)
Edgewise Therapeutics (EWTX) posted Income from Continuing Operations of 49013000.0 for Q1 2026, up 9.26% sequentially from 54016000.0 in Q4 2025, and down 20.14% YoY from 61370419.36 in Q1 2025.
Powered by 
Analysis
Edgewise Therapeutics (EWTX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Edgewise Therapeutics has reported Income from Continuing Operations for 7 years, with the latest figure at 49013000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 20.14% year-over-year to 49013000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 179810000.0 (down 18.49% YoY) and the FY2025 annual result came in at 423521000.0, down 5.56% from the prior year.
- Income from Continuing Operations grew to 49013000.0 in Q1 2026 per EWTX's latest filing, from 54016000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 16524000.0 in Q2 2022 and troughed at 54016000.0 in Q4 2025.
- A 5-year average of 32624823.53 and a median of 32563000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations sank 163.55% in 2022, then dropped 10.91% in 2025.
- Over 5 years, Income from Continuing Operations stood at 19847000.0 in 2022, then tumbled by 52.14% to 30196000.0 in 2023, then plunged by 46.58% to 44262000.0 in 2024, then decreased by 22.04% to 54016000.0 in 2025, then advanced by 9.26% to 49013000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 49013000.0, 54016000.0, and 40666000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Edgewise Therapeutics | 4.65 Bn | 4.65 Bn | - | -57.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -57.33 Mn |
| Mar 31, 2026 | -49.01 Mn |
| Dec 31, 2025 | -50.22 Mn |
| Sep 30, 2025 | -40.67 Mn |
| Jun 30, 2025 | -36.12 Mn |
| Mar 31, 2025 | -40.80 Mn |
| Dec 31, 2024 | -39.66 Mn |
| Sep 30, 2024 | -34.13 Mn |
| Jun 30, 2024 | -31.50 Mn |
| Mar 31, 2024 | -28.53 Mn |
| Dec 31, 2023 | -30.14 Mn |
| Sep 30, 2023 | -25.71 Mn |
| Jun 30, 2023 | -21.47 Mn |
| Mar 31, 2023 | -22.84 Mn |
| Dec 31, 2022 | -19.42 Mn |
| Sep 30, 2022 | -17.50 Mn |
| Jun 30, 2022 | -16.07 Mn |
| Mar 31, 2022 | -14.66 Mn |
| Dec 31, 2021 | -12.70 Mn |
| Sep 30, 2021 | -12.95 Mn |